Jade Biosciences Widens Loss as Pipeline Data Multiplies
Jade Biosciences reported a net loss of $55.8 million in the second quarter, even as cash climbed to $461.2 million after a $172.5 million stock offering funded three drug programs advancing at once.
Jade Biosciences (JBIO) posted a net loss of $55.8 million for the second quarter of 2026, up from $32.1 million a year earlier, as the clinical-stage biotech ramped spending across a widening pipeline. Net loss per share improved to $(0.76) from $(0.86), a result of a weighted-average share count that more than doubled to 61.1 million from 28.4 million, largely reflecting the equity raised during the quarter.
The spending increase tracked new clinical activity rather than a change in strategy. Research and development expenses rose to $50.1 million from $22.5 million a year earlier, up roughly 122%, driven by CMC costs, clinical trial activity, one-time development milestone payments and higher personnel costs. General and administrative expenses rose to $8.9 million from $5.2 million, up about 70%, on personnel costs and stock-based compensation. Stock-based compensation itself more than tripled within R&D, to $10.6 million from $2.6 million, and roughly doubled within G&A, to $3.0 million from $1.4 million.
Jade funded that spending with a $172.5 million public offering completed during the quarter, a transaction not mentioned in the company's prior release on June 26. Cash, cash equivalents and investments rose to $461.2 million as of June 30 from $336.2 million at year-end 2025, a $125 million increase that extends its runway into the fourth quarter of 2028. Total assets grew to $472.1 million from $349.8 million over the same period, while total liabilities rose to $32.2 million from $17.3 million.
The capital raise coincided with the first public disclosure of clinical results for JADE101, the company's lead antibody candidate for IgA nephropathy. Jade reported positive interim Phase 1 data showing roughly 70% mean reduction in IgA from baseline after a single 700 milligram dose, along with support for a subcutaneous maintenance regimen dosed every 12 weeks. The June 26 release had contained no such data, only a board appointment.
Dosing began this quarter in the Phase 2 JUNIPER trial of JADE101 in IgA nephropathy, with a Phase 3 registrational trial now targeted for the first half of 2027. Jade also began dosing in a Phase 1 trial of JADE201, an anti-BAFF-R candidate for rheumatoid arthritis, and disclosed JADE301, an anti-IFN-ß program for dermatomyositis, with a Phase 1 healthy-volunteer trial timeline set for the fourth quarter of 2026. None of the three programs' clinical progress appeared in the company's June 26 release.
The quarter's results show a company converting a recent capital raise directly into clinical throughput, moving three programs into or through early-stage trials within a single reporting period. The wider net loss reflects that acceleration rather than a deterioration in the underlying business, with the extended cash runway giving Jade room to carry JADE101 toward its 2027 Phase 3 target without an immediate need to return to the capital markets.